Vimarsana
Biggest News Aggregation in the World

Arthex Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arthex Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arthex Biotech Today - Breaking & Trending Today

ARTHEx Biotech Announces Oral Presentation on ATX-01 at the Oligonucleotide & Peptide Therapeutics (TIDES) Conference 2024 - Vimarsana News

ARTHEx Biotech Announces Oral Presentation on ATX-01 at the Oligonucleotide & Peptide Therapeutics (TIDES) Conference 2024

Published: April 19, 2024

/PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,...

Source: prnewswire.com
Related Topics:
United StatesJuniper PointAmy ConradCompany ContactPeptide TherapeuticsBiotech Executive ChairmanSkeletal MuscleNervous SystemDual Therapeutic ApproachOligonucleotide DiscoveryOrphan Drug DesignationMyotonic Dystrophy TypeArthex BiotechHealth Care Amp HospitalsMedical PharmaceuticalsClinical Trials Amp Medical Discoveries
ARTHEx Biotech Announces Participation at the 23rd Annual Needham Virtual Healthcare Conference - Vimarsana News

ARTHEx Biotech Announces Participation at the 23rd Annual Needham Virtual Healthcare Conference

Published: April 3, 2024

/PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,...

Source: prnewswire.com
Related Topics:
Amy ConradCompany ContactNeedham Virtual Healthcare ConferenceArthex Biotech
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1) - Vimarsana News

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

Published: February 28, 2024

/PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,...

Source: prnewswire.com
Related Topics:
Amy ConradJudith WalkerNicholas JohnsonVirginia Commonwealth UniversityDepartment Of NeurologyDrug AdministrationCompany ContactMyotonic Dystrophy TypeChief Medical OfficerVice ChairOrphan Drug DesignationArthex Biotech
ARTHEx Biotech to Participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum - Vimarsana News

ARTHEx Biotech to Participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum

Published: October 11, 2023

/PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,...

Source: prnewswire.com
Related Topics:
Amy ConradCompany ContactNeedham Private Biotech Company VirtualAnnual Needham Private Biotech Company VirtualMedia ContactArthex Biotech
ARTHEx Biotech to Present at Chardan's 7th Annual Genetic Medicines Conference - Vimarsana News

ARTHEx Biotech to Present at Chardan's 7th Annual Genetic Medicines Conference

Published: September 28, 2023

/PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,...

Source: prnewswire.com
Related Topics:
Amy ConradCompany ContactAnnual Genetic MedicinesArthex Biotech